Ann: PYC Investor Update Presentation, page-21

Previously it had been mentioned that industry interest in PYC’s ophthalmology assets was muted; greater interest was in CNS and kidney drugs. It seems that this has changed @hottod

Why has it changed i.e. why are PYC's ophthalmology assets suddenly attracting interest? Of course, one can only speculate but a good place to start is to refer to the GSK collaboration with Wave Life Sciences. The discovery collaboration which has an initial four year term, will allow GSK to advance up to eight preclinical programs including Wave's first-in-class RNA editing program, WVE-006 to treat alpha-1 antitrypsin deficiency, a disease that impacts the lungs and liver.

My point is that the ophthalmology assets including retinitis pigmentosa Type 11 could now be seen as the point of entry to access the PYC oligonucleotide platform. Okay, you might not be so much interested in RP11 but its one of three first-in-class drugs each with a billion dollar plus market. First, pursue haploinsufficiency diseases with unmet need with potential six-fold success rates and in turn validate the platform. Eventually the four powerful forces driving the interest in haploinsufficiency diseases could be relaxed and maybe it becomes three powerful forces expanding into a wider range of disease indications.